Mark Mcdade Insider Profile

4 Followers
Mark Mcdade, Director at Five Prime Therapeutics, holds 0.00 shares in Five Prime Therapeutics (Ticker: FPRX), holds 0.00 shares in Icosavax (Ticker: ICVX), holds 742.21K shares in Tourmaline Bio (Ticker: TRML). Most recently, Mark Mcdade ― shares of Five Prime Therapeutics on ― for an estimated value of ―.
tipranks
Mark Mcdade

Mark Mcdade
Five Prime Therapeutics (FPRX)
Director

Ranked #57,111 out of 99,335 Corporate Insiders

Profitable Transactions

0%
0 out of 2 Profitable Transactions

Average Return

-8.80%
Average return per transaction
Time Frame
1 Year
Compare to
No Benchmark

Insider Holdings

$21M
99.84%
0.16%
0.00%
A breakdown of Mark Mcdade's holdings

Insider Roles

Tourmaline Bio
(TRML)
Director
Journey Medical Corp
(DERM)
Director
Cytokinetics
(CYTK)
Director
Roles that Mark Mcdade holds in companies

Most Profitable Insider Trade

Stock:
Icosavax
(ICVX)
Rating:Informative Buy
Date:Apr 05, 2022 - Apr 05, 2023
Return:-3.80%
The most profitable trade made by Mark Mcdade

Mark Mcdade's Trading History

Company Name
Last Transaction Date
Insider Position
Last Transaction
Last Transaction Amount
Holding Value
FPRX
Five Prime Therapeutics
$0.00
AIMT
Aimmune Therapeutics
Oct 14, 2020
Uninformative Sell
270.48K
$0.00
ICVX
Icosavax
Feb 20, 2024
Uninformative Sell
$0.00
Tourmaline Bio
Jan 31, 2024
Director
Informative Buy
3.25M
$21.02M
Journey Medical Corp
Director
$33.48K
~DERM
Dermira
$112.50K
PDLI
PDL BioPharma
$114.30K
Cytokinetics
Director
$0.00
List of latest transactions for each holding click on a transaction to see Mark Mcdade's performance on stock

Mark Mcdade insider profile FAQ

What is the percentage of profitable transactions made by Mark Mcdade?
The percentage of profitable transactions made by Mark Mcdade is 0%.
    What is the average return per transaction made by Mark Mcdade?
    The average return per transaction made by Mark Mcdade is -8.80%.
      What stocks does Mark Mcdade hold?
      Mark Mcdade holds: FPRX, AIMT, ICVX, TRML, DERM, ~DERM, PDLI, CYTK stocks.
        What was Mark Mcdade’s latest transaction?
        Mark Mcdade latest transaction was an Uninformative Buy of ―.
          What was Mark Mcdade's most profitable transaction?
          Mark Mcdade’s most profitable transaction was an Informative Buy of ICVX stock on April 5, 2022. The return on the trade was -3.80%.
            What is Mark Mcdade's role in Five Prime Therapeutics?
            Mark Mcdade's role in Five Prime Therapeutics is Director.
              How can I follow the stock ratings of top corporate insiders?
              Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.